{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:14:07Z","timestamp":1768414447556,"version":"3.49.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.eimc.2020.01.021","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T08:01:01Z","timestamp":1583222461000},"page":"87-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevention and therapy of viral infections in patients with solid organ transplantation"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8765-3466","authenticated-orcid":false,"given":"Jose Tiago","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0315-8001","authenticated-orcid":false,"given":"Mario","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-8255","authenticated-orcid":false,"given":"Jos\u00e9 Mar\u00eda","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2020.01.021_bib0515","year":"2018","journal-title":"Actividad de Donaci\u00f3n y Trasplante Espa\u00f1a"},{"key":"10.1016\/j.eimc.2020.01.021_bib0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ajt.13201","article-title":"OPTN\/SRTR 2013 Annual Data Report: economics","volume":"Suppl.","author":"Schnitzler","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0525","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2215\/CJN.10590918","article-title":"Secular trends in the cost of immunosuppressants after solid organ transplantation in the United States","volume":"14","author":"Helmuth","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.eimc.2020.01.021_bib0530","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccc.2018.08.011","article-title":"Complications of solid organ transplantation: cardiovascular, neurologic, renal, and gastrointestinal","volume":"35","author":"Sen","year":"2019","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.eimc.2020.01.021_bib0535","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/1469-0691.12593","article-title":"From the classic concepts to modern practice","volume":"Suppl.","author":"Fishman","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimc.2020.01.021_bib0540","doi-asserted-by":"crossref","first-page":"a015669","DOI":"10.1101\/cshperspect.a015669","article-title":"Opportunistic infections \u2013 coming to the limits of immunosuppression?","volume":"3","author":"Fishman","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.eimc.2020.01.021_bib0545","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/1744666X.2018.1476852","article-title":"Anti-infective chemoprophylaxis after solid-organ transplantation","volume":"14","author":"Deziel","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.eimc.2020.01.021_bib0550","doi-asserted-by":"crossref","first-page":"e13563","DOI":"10.1111\/ctr.13563","article-title":"AST ID Community of Practice Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice","author":"Danziger-Isakov","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0555","first-page":"19","article-title":"Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting","author":"Hakimi","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.021_bib0560","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MOP.0000000000000445","article-title":"Management of post-transplant lymphoproliferative disorders","volume":"29","author":"Llaurador","year":"2017","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.eimc.2020.01.021_bib0565","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.semnephrol.2016.05.011","article-title":"Alpha herpes virus infections among renal transplant recipients","volume":"36","author":"Abad","year":"2016","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.eimc.2020.01.021_bib0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ajt.12002","article-title":"Overview: cytomegalovirus and the herpesviruses in transplantation","volume":"Suppl.","author":"Fishman","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0575","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.4437","article-title":"The pathogenesis of human cytomegalovirus","volume":"235","author":"Griffiths","year":"2015","journal-title":"J Pathol"},{"key":"10.1016\/j.eimc.2020.01.021_bib0580","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM196411122712001","article-title":"Infectious pulmonary disease in patients receiving immunosuppressive therapy for organ transplantation","volume":"271","author":"Hill","year":"1964","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2020.01.021_bib0585","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1001\/jama.1989.03420240121038","article-title":"The indirect effects of cytomegalovirus infection on the outcome of organ transplantation","volume":"261","author":"Rubin","year":"1989","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2020.01.021_bib0590","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3947\/ic.2013.45.3.260","article-title":"Cytomegalovirus infections in solid organ transplantation: a review","volume":"45","author":"Ramanan","year":"2013","journal-title":"Infect Chemother"},{"key":"10.1016\/j.eimc.2020.01.021_bib0595","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.021_bib0600","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.trre.2014.01.001","article-title":"The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients","volume":"28","author":"Roman","year":"2014","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.eimc.2020.01.021_bib0605","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1086\/605637","article-title":"Risk factors, clinical features, and outcomes of listeriosis in solid-organ transplant recipients: a matched case\u2013control study","volume":"49","author":"Fern\u00e1ndez-Sab\u00e8","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.021_bib0610","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/ciy682","article-title":"A multicenter case\u2013control study of the effect of acute rejection and cytomegalovirus infection on Pneumocystis pneumonia in solid organ transplant recipients","volume":"68","author":"Hosseini-Moghaddam","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.021_bib0615","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1086\/430602","article-title":"Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case\u2013control study","volume":"41","author":"Gavalda","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.021_bib0620","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11046-015-9875-4","article-title":"Invasive fungal infections in renal transplant recipients: epidemiology and risk factors","volume":"180","author":"Sahin","year":"2015","journal-title":"Mycopathologia"},{"key":"10.1016\/j.eimc.2020.01.021_bib0625","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.healun.2015.03.015","article-title":"Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation","volume":"34","author":"Delgado","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0630","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0140-6736(88)92356-2","article-title":"Cytomegalovirus infection and donor\/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation","volume":"2","author":"O\u2019Grady","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2020.01.021_bib0635","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/hep.1840160202","article-title":"Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome","volume":"16","author":"Arnold","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2020.01.021_bib0640","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1111\/ajt.13486","article-title":"The impact of infection on chronic allograft dysfunction and llograft survival after solid organ transplantation","volume":"15","author":"Martin-Gandul","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0645","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/QCO.0000000000000409","article-title":"Viral infections in solid organ transplant recipients: novel updates and a review of the classics","volume":"30","author":"Haidar","year":"2017","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.021_bib0650","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/tri.12586","article-title":"Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice","volume":"28","author":"Fern\u00e1ndez-Ruiz","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.eimc.2020.01.021_bib0655","first-page":"CD004759","article-title":"Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients","volume":"1","author":"Hill","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eimc.2020.01.021_bib0660","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/ajt.13327","article-title":"Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses","volume":"15","author":"Tedesco-Silva","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0665","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000002626","article-title":"Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM Study","volume":"103","author":"Tedesco-Silva","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.eimc.2020.01.021_bib0670","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.trre.2016.04.001","article-title":"Management of cytomegalovirus infection in solid organ transplant recipients: SET\/GESITRA-SEIMC\/REIPI recommendations","volume":"30","author":"Torre-Cisneros","year":"2016","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.eimc.2020.01.021_bib0675","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0680","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","article-title":"Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group","volume":"340","author":"Lowance","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2020.01.021_bib0685","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2215\/CJN.07020714","article-title":"Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation","volume":"10","author":"Reischig","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.eimc.2020.01.021_bib0690","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/s12879-018-3493-y","article-title":"Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial","volume":"18","author":"Reischig","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.021_bib0695","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1016\/j.transproceed.2016.06.062","article-title":"Effect of cytomegalovirus infection on survival of older kidney transplant patients (D+\/R+): impact of valganciclovir prophylaxis versus preemptive therapy","volume":"48","author":"Luna","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.eimc.2020.01.021_bib0700","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.idc.2018.04.008","article-title":"Prevention and treatment of cytomegalovirus nfections in solid organ transplant recipients","volume":"32","author":"Koval","year":"2018","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.eimc.2020.01.021_bib0705","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1600-6143.2008.02513.x","article-title":"Interlaboratory comparison of cytomegalovirus viral load assays","volume":"9","author":"Pang","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0710","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.healun.2018.04.001","article-title":"Monitoring of early humoral immunity to identify lung recipients at risk for development of serious infections: a multicenter prospective study","volume":"37","author":"Sarmiento","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0715","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.healun.2016.10.004","article-title":"Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: a multicenter prospective study","volume":"36","author":"Sarmiento","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0720","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/S0041-1345(01)02101-7","article-title":"Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study","volume":"33","author":"Snydman","year":"2001","journal-title":"Transplant Proc"},{"key":"10.1016\/j.eimc.2020.01.021_bib0725","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1034\/j.1600-6143.2003.00074.x","article-title":"Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction","volume":"3","author":"Weill","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0730","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1097\/00007890-200111270-00012","article-title":"Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone","volume":"72","author":"Valantine","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.eimc.2020.01.021_bib0735","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1034\/j.1399-3062.2001.00010.x","article-title":"Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation","volume":"3 Suppl","author":"Zamora","year":"2001","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.021_bib0740","doi-asserted-by":"crossref","first-page":"e13560","DOI":"10.1111\/ctr.13560","article-title":"Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: a systematic review and meta-analysis","volume":"33","author":"Bourassa-Blanchette","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0745","doi-asserted-by":"crossref","first-page":"e13625","DOI":"10.1111\/ctr.13625","article-title":"Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: a systematic review and meta-analysis \u2013 Part II: Non-kidney transplant","volume":"33","author":"Bourassa-Blanchette","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0750","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1093\/cid\/cix696","article-title":"Role of secondary prophylaxis with valganciclovir in the prevention of recurrent cytomegalovirus disease in solid organ transplant recipients","volume":"65","author":"Gardiner","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.021_bib0755","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.antiviral.2013.10.014","article-title":"Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus","volume":"101","author":"Germi","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.eimc.2020.01.021_bib0760","first-page":"32","article-title":"Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: a case series and review of the literature","author":"Silva","year":"2018","journal-title":"Clin Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0765","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/IDR.S180908","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review","volume":"12","author":"El Helou","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.eimc.2020.01.021_bib0770","first-page":"63","article-title":"Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis","author":"Turner","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.01.021_bib0775","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0780","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MOT.0000000000000666","article-title":"Updates on antiviral drugs for cytomegalovirus prevention and treatment","volume":"24","author":"Kotton","year":"2019","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0785","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.eimc.2020.01.021_bib0790","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","article-title":"Efficacy and safety of maribavir dosed at 100mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial","volume":"12","author":"Winston","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0795","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2020.01.021_bib0800","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/cid\/cis818","article-title":"State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician","volume":"55","author":"Egli","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.021_bib0805","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1038\/cti.2014.3","article-title":"Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation","volume":"3","author":"Fern\u00e1ndez-Ruiz","year":"2014","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.eimc.2020.01.021_bib0810","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1399-3062.2006.00199.x","article-title":"Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV","volume":"9","author":"Walker","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.021_bib0815","doi-asserted-by":"crossref","first-page":"e0189488","DOI":"10.1371\/journal.pone.0189488","article-title":"Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients","volume":"12","author":"Lee","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.eimc.2020.01.021_bib0820","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/tri.13110","article-title":"Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study","volume":"31","author":"Banas","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.eimc.2020.01.021_bib0825","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cyto.a.20641","article-title":"Analytical performance of a standardized single-platform MHC tetramer assay for the identification enumeration of CMV-specific CD8+T","volume":"73","author":"Brooimans","year":"2008","journal-title":"Cytometry Lymphocytes A"},{"key":"10.1016\/j.eimc.2020.01.021_bib0830","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/ajt.12049","article-title":"Pretransplant interferon-\u03b3 secretion by CMV-specific CD8+T cells informs the risk of CMV replication after transplantation","volume":"13","author":"Cantis\u00e1n","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0835","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/ajt.12256","article-title":"Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation","volume":"13","author":"Bestard","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0840","doi-asserted-by":"crossref","first-page":"381.e1","DOI":"10.1016\/j.cmi.2018.05.010","article-title":"Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment","volume":"25","author":"Fern\u00e1ndez-Ruiz","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimc.2020.01.021_bib0845","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.021_bib0850","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/TP.0000000000002454","article-title":"A randomized study of Quantiferon CMV-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation","volume":"103","author":"Westall","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.eimc.2020.01.021_bib0855","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/TP.0b013e31823c1cd4","article-title":"Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia","volume":"93","author":"Lisboa","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.eimc.2020.01.021_bib0860","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cid\/ciy549","article-title":"Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label phase I clinical trial","volume":"68","author":"Smith","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.021_bib0865","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.DMIH2-0011-2015","article-title":"Epstein-Barr virus","volume":"4","author":"Nowalk","year":"2016","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.eimc.2020.01.021_bib0870","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1097\/TXD.0000000000000557","article-title":"Epstein-Barr virus-positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management","volume":"2","author":"Nijland","year":"2016","journal-title":"Transplant Direct"},{"key":"10.1016\/j.eimc.2020.01.021_bib0875","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-transplantation lymphoproliferative disorders in adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2020.01.021_bib0880","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ajt.12004","article-title":"Epstein-Barr virus infection and posttransplant lymphoproliferative disorder","volume":"Suppl.","author":"Green","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0885","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2146\/ajhp120770","article-title":"Risk of posttransplant lymphoproliferative disorder associated with use of belatacept","volume":"70","author":"Martin","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.eimc.2020.01.021_bib0890","doi-asserted-by":"crossref","first-page":"e13652","DOI":"10.1111\/ctr.13652","article-title":"Post-transplant lymphoproliferative disorders Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","author":"Allen","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0895","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/1469-0691.12534","article-title":"Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients","volume":"Suppl.","author":"San-Juan","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimc.2020.01.021_bib0900","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2015.02.002","article-title":"Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe Results of the ESGICH Questionnaire-based Cross-sectional Survey","volume":"21","author":"San-Juan","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimc.2020.01.021_bib0905","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2010.08160.x","article-title":"Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients \u2013 BCSH and BTS Guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eimc.2020.01.021_bib0910","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.transproceed.2018.01.004","article-title":"Progressive multifocal leukoencephalopathy following combined rituximab-based immune-chemotherapy for post-transplant lymphoproliferative disorder in a renal transplant recipient: a case report","volume":"50","author":"Windpessl","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.eimc.2020.01.021_bib0915","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","article-title":"Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial","volume":"35","author":"Trappe","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eimc.2020.01.021_bib0920","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s12185-017-2381-3","article-title":"Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases","volume":"107","author":"Kim","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.eimc.2020.01.021_bib0925","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1111\/ajt.13244","article-title":"Radioimmunotherapy (90Y-Ibritumomab Tiuxetan) for posttransplant lymphoproliferative disorders after prior exposure to rituximab","volume":"15","author":"Rossignol","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0930","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1111\/ajt.14192","article-title":"Preventive strategies against cytomegalovirus and incidence of alpha-herpesvirus infections in solid organ transplant recipients: a nationwide cohort study","volume":"17","author":"Martin-Gandul","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0935","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/tri.13076","article-title":"Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count. A single-center cohort study","volume":"31","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.eimc.2020.01.021_bib0940","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1399-3062.2010.00547.x","article-title":"Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients","volume":"13","author":"Pergam","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.021_bib0945","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.healun.2007.09.028","article-title":"Incidence and clinical characteristics of herpes zoster after lung transplantation","volume":"27","author":"Manuel","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0950","doi-asserted-by":"crossref","first-page":"e13622","DOI":"10.1111\/ctr.13622","article-title":"AST Infectious Diseases Community of Practice Varicella zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","author":"Pergam","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0955","doi-asserted-by":"crossref","first-page":"e13526","DOI":"10.1111\/ctr.13526","article-title":"AST Infectious Diseases Community of Practice Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","author":"Lee","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0960","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa035144","article-title":"Once-daily valacyclovir to reduce the risk of transmission of genital herpes","volume":"350","author":"Corey","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2020.01.021_bib0965","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ctr.12227","article-title":"Predictors and outcomes of acyclovir-resistant herpes simplex virus infection among hematopoietic cell transplant recipients: case-case-control investigation","volume":"28","author":"Patel","year":"2014","journal-title":"Clin Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0970","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbmt.2010.06.020","article-title":"Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients","volume":"17","author":"Kim","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0975","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00705-016-2794-y","article-title":"Polyomaviridae study group of the international committee on taxonomy of virus A taxonomy update for the family Polyomaviridae","volume":"161","author":"Calvignac-Spencer","year":"2016","journal-title":"Arch Virol"},{"key":"10.1016\/j.eimc.2020.01.021_bib0980","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/ajt.12110","article-title":"AST Infectious Diseases Community of Practice BK polyomavirus in solid organ transplantation","volume":"Suppl.","author":"Hirsch","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0985","doi-asserted-by":"crossref","first-page":"e13528","DOI":"10.1111\/ctr.13528","article-title":"AST Infectious Diseases Community of Practice BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","author":"Hirsch","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.eimc.2020.01.021_bib0990","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.2215\/CJN.08261109","article-title":"Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation","volume":"5","author":"Gabardi","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.eimc.2020.01.021_bib0995","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/TP.0b013e31826ec74e","article-title":"Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year","volume":"94","author":"Wojciechowski","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.eimc.2020.01.021_bib1000","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1001\/jama.2014.14721","article-title":"Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial","volume":"312","author":"Knoll","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2020.01.021_bib1005","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2215\/CJN.04230413","article-title":"Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial","volume":"9","author":"Lee","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.eimc.2020.01.021_bib1010","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1128\/AAC.00974-10","article-title":"1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells","volume":"54","author":"Rinaldo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.01.021_bib1015","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1128\/AAC.00238-15","article-title":"Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells","volume":"59","author":"Tylden","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.01.021_bib1020","doi-asserted-by":"crossref","first-page":"e5226","DOI":"10.1097\/MD.0000000000005226","article-title":"Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection","volume":"95","author":"Faure","year":"2016","journal-title":"Medicine (Baltimore)"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X20300288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X20300288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:06:37Z","timestamp":1759323997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X20300288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":102,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0213005X20300288"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2020.01.021","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention and therapy of viral infections in patients with solid organ transplantation","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2020.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}